Skip to Main content Skip to Navigation
Journal articles

Vaccination contre la COVID-19 des patients atteints de cancer solide : revue et préconisations d’un inter-groupe oncologique français (CGO, TNCD, UNICANCER)

David Tougeron 1, * Barbara Seitz-Polski 2 Maxime Hentzien 3 Firouzé Bani-Sadr 3 Jean Bourhis 4 Michel Ducreux 5, 6, 7 Sébastien Gaujoux 8 Philippe Gorphe 6, 9 Boris Guiu 10 Anne Claire Hardy-Bessard Khê Hoang Xuan 8 Florence Huguet 11 Thierry Lecomte 12 Astrid Lièvre 13, 14 Christophe Louvet 15 Léon Maggiori 16 Pascale Mariani 17 Pierre Michel 18 Amélie Servettaz 3 Juliette Thariat 19 Virginie Westeel 20 Thomas Aparicio 16 Jean Yves Blay 21 Olivier Bouché 3
Abstract : The COVID-19 pandemic has a major impact at all stages of cancer treatment. Risk of death from COVID-19 in patients treated for a cancer is high. COVID-19 vaccines represent a major issue to decrease the rate of severe forms of the COVID-19 cases and to maintain a normal cancer care. It is difficult to define the target population for vaccination due to the limited data available and the lack of vaccine doses available. It appears theoretically important to vaccinate patients with active cancer treatment or treated since less than three years, as well as their family circle. In France, patients actually defined at "high risk" for priority access to vaccination are those with a cancer treated by chemotherapy. A panel of experts recently defined another "very high-priority" population, which includes patients with curative or palliative first or second-line chemotherapy, as well as patients requiring surgery or radiotherapy involving a large lung volume, lymph nodes and/or of hematopoietic tissue. Ideally, it is best to vaccinate before cancer treatment. Despite the lack of published data, COVID-19 vaccines can also be performed during chemotherapy by avoiding periods of bone marrow aplasia and if possible, to do it in cancer care centers. It is necessary to implement cohorts with immunological and clinical monitoring of vaccinated cancer patients. To conclude, considering the current state of knowledge, the benefit-risk ratio strongly favours COVID-19 vaccination of all cancer patients.
Document type :
Journal articles
Complete list of metadata
Contributor : Laurent Jonchère <>
Submitted on : Friday, June 11, 2021 - 3:26:39 PM
Last modification on : Tuesday, July 13, 2021 - 3:29:28 AM
Long-term archiving on: : Sunday, September 12, 2021 - 7:58:41 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2021-10-12

Please log in to resquest access to the document



David Tougeron, Barbara Seitz-Polski, Maxime Hentzien, Firouzé Bani-Sadr, Jean Bourhis, et al.. Vaccination contre la COVID-19 des patients atteints de cancer solide : revue et préconisations d’un inter-groupe oncologique français (CGO, TNCD, UNICANCER). Bulletin du Cancer, John Libbey Eurotext, 2021, ⟨10.1016/j.bulcan.2021.03.009⟩. ⟨hal-03225072⟩



Record views